Open AccessRecombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma
Author(s) -
Chen Chen,
Songran Liu,
Shu Zhou,
Xiaohui Li,
Xiaohui Wang,
Yijing Tao,
Hui Chang,
Wen Zhang,
Wenfei Li,
S. Kevin Zhou,
Yunfei Xia
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016592
Subject(s) - medicine , nasopharyngeal carcinoma , refractory (planetary science) , endostatin , oncology , pharmacology , vegf receptors , radiation therapy , physics , astrobiology
Rationale: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. Patient concerns: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. Diagnosis: They were diagnosed as refractory nasopharyngeal carcinoma. Interventions: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. Outcomes: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. Lessons: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.